CGEN - Compugen
Compugen Logo

CGEN - Compugen

https://cgen.com
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Compugen Ltd., a clinical-stage therapeutic discovery and development company, is engaged in the research, development, and commercialization of therapeutic candidates and products in Israel, the United States, and Europe. The company is headquartered in Holon, Israel.

52W High
$2.66
52W Low
$1.13
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
2.59
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-19.16
EV/Revenue (<3 favorable)
1.62
P/S (TTM) (<3 favorable)
6.04
P/B (<3 favorable)
2.66
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
2.03%
Institutions (25–75% balanced)
16.56%
Shares Outstanding
93,535,000
Float
91,623,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
22,144,000
Gross Profit (TTM)
13,803,000
EPS (TTM)
-0.22
Profit Margin (>10% good)
-0.88%
Operating Margin (TTM) (higher better)
-6.71%
ROE (TTM) (>15% strong)
-0.36%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-0.81
Momentum
Value
N/A
Previous
N/A
Trend
—
Signal Cross
No cross
As of
—